Caratterizzazione sperimentale della produzione in aria di 41-Ar nell'impiego di un ciclotrone per uso biomedico

Negli ultimi anni l'utilizzo di ciclotroni per la produzione di radionuclidi, impiegati nell'ambito della Medicina Nucleare, è diventato un processo sempre più diffuso e numerosi sono i modelli commercialmente disponibili. L'impiego di questo tipo di apparecchiature porta a considerare questioni rilevanti legate alla radioprotezione che coinvolgono una serie di aspetti complessi sia nella fase progettuale del sistema, sia nell'ottenimento delle necessarie autorizzazioni. In particolare, uno dei problemi radioprotezionistici da affrontare è legato alla dispersione in ambiente di aeriformi radioattivi, prodotti dall'interazione di flussi di particelle secondarie con l'aria. In questo lavoro di tesi, svolto presso il Servizio di Fisica Sanitaria dell'Ospedale Sant'Orsola di Bologna, si è cercato di caratterizzare l'emissione di tali gas radioattivi considerando l'effetto del sistema di ventilazione. E' stata eseguita un'estesa campagna di misurazioni in diversi punti di campionamento, collocati lungo il percorso di estrazione dell'aria: dal bunker fino all'immissione in ambiente. Sono stati ideati e realizzati dei compatti sistemi di campionamento che hanno permesso di definire, attraverso un sistema di spettrometria gamma equipaggiato con rivelatore al HPGe, una sistematica procedura per la determinazione di concentrazione di attività. I risultati ottenuti mostrano come, durante la routine di produzione di 18F mediante ciclotrone, il processo più rilevante di attivazione dell'aria sia la produzione di 41Ar (T1/2=109.34 minuti), unico radionuclide identificato in tutte le misurazioni. Infine, sulla base dei dati sperimentali ottenuti, è stata effettuata una valutazione della dose rilasciata alla popolazione locale. Il risultato, pari a 0.19 µSv/anno, può essere considerato trascurabile rispetto alla soglia di "non rilevanza radiologica", a dimostrazione di come le tipiche procedure in ambito di Medicina Nucleare possano essere considerate del tutto giustificate.

Primary tumors of the submandibular glands: a retrospective study based on 41 cases

We report our experience on the diagnostic approach, treatment, and follow-up of primary submandibular gland tumors. Retrospective review. Tertiary referral center. Forty-one adult patients, 22 male and 19 female, with primary submandibular gland tumors, 20 benign and 21 malignant. Age, gender, clinical findings, cyto- and histopathology, treatment and outcome were analyzed. Most tumors presented as a painless submandibular mass. Thirty three patients underwent a fine needle aspiration, the sensitivity, specificity and accuracy of which--in detecting malignant tumors--were 79%, 100% and 88%, respectively. Preoperative radiological imaging was performed in 30 cases. Patients with benign tumors were treated with surgery. Most malignant tumors were treated with a combined modality, including neck dissection and radiation therapy. Five patients developed a postoperative complication. Recurrent disease was encountered in 5 malignant tumors. The 2, 5 and 10 year disease-specific survival of patients with malignancy were 84%, 75% and 41%, respectively. The preoperative assessment of the nature of submandibular gland tumors remains challenging. Aggressive treatment of patients with malignant disease may help to avoid poor prognosis.

Long-term stability of contour augmentation with early implant placement following single tooth extraction in the esthetic zone: a prospective, cross-sectional study in 41 patients with a 5- to 9-year follow-up

BACKGROUND Early implant placement with simultaneous contour augmentation is documented with short- and medium-term studies. The long-term stability of contour augmentation is uncertain. METHODS In this prospective, cross-sectional study, 41 patients with an implant-borne single crown were examined twice, in 2006 and 2010. Clinical, radiologic, and esthetic parameters were assessed at both examinations. In addition, a cone beam computed tomographic (CBCT) image was obtained during the second examination to assess the dimensions of the facial bone wall. RESULTS All 41 implants demonstrated ankylotic stability without signs of peri-implant infection at both examinations. The clinical parameters remained stable over time. Satisfactory esthetic outcomes were noted, as assessed by the pink and white esthetic score (PES/WES) indices. Overall, the PES scores were slightly higher than the WES scores. None of the implants developed mucosal recession over time, as confirmed by values of the distance between implant shoulder and mucosal margin and cast measurements. The periapical radiographs yielded stable peri-implant bone levels, with a mean distance between implant shoulder and first visible bone-implant contact value of 2.18 mm. The CBCT analysis demonstrated a mean thickness of the facial bone wall ≈2.2 mm. In two implants (4.9%) no facial bone wall was detectable radiographically. CONCLUSIONS This prospective cross-sectional study demonstrates stable peri-implant hard and soft tissues for all 41 implants examined and satisfactory esthetic outcomes overall. The follow-up of 5 to 9 years confirmed again that the risk for mucosal recession is low with early implant placement. In addition, contour augmentation with guided bone regeneration was able to establish and maintain a facial bone wall in 95% of patients.

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

BACKGROUND We conducted a randomized, phase II, multicenter study to evaluate the anti-epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with chemoradiotherapy (CRT) with standard-dose capecitabine as neoadjuvant treatment for wild-type KRAS locally advanced rectal cancer (LARC). PATIENTS AND METHODS Patients with wild-type KRAS, T3-4 and/or N+ LARC were randomly assigned to receive CRT with or without P (6 mg/kg). The primary end-point was pathological near-complete or complete tumor response (pNC/CR), defined as grade 3 (pNCR) or 4 (pCR) histological regression by Dworak classification (DC). RESULTS Forty of 68 patients were randomly assigned to P + CRT and 28 to CRT. pNC/CR was achieved in 21 patients (53%) treated with P + CRT [95% confidence interval (CI) 36%-69%] versus 9 patients (32%) treated with CRT alone (95% CI: 16%-52%). pCR was achieved in 4 (10%) and 5 (18%) patients, and pNCR in 17 (43%) and 4 (14%) patients. In immunohistochemical analysis, most DC 3 cells were not apoptotic. The most common grade ≥3 toxic effects in the P + CRT/CRT arm were diarrhea (10%/6%) and anastomotic leakage (15%/4%). CONCLUSIONS The addition of panitumumab to neoadjuvant CRT in patients with KRAS wild-type LARC resulted in a high pNC/CR rate, mostly grade 3 DC. The results of both treatment arms exceeded prespecified thresholds. The addition of panitumumab increased toxicity.